|
|
Volumn 374, Issue 3, 2016, Pages 286-
|
|
Chemohormonal therapy in hormone-sensitive prostate cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANDROGEN;
ANTIANDROGEN;
DOCETAXEL;
TUMOR MARKER;
ANTINEOPLASTIC AGENT;
TAXOID;
ANDROGEN DEPRIVATION THERAPY;
CANCER HORMONE THERAPY;
CANCER PATIENT;
CANCER STAGING;
CANCER SURVIVAL;
CASTRATION RESISTANT PROSTATE CANCER;
CHEMOSENSITIVITY;
DISEASE ACTIVITY;
HIGH RISK PATIENT;
HUMAN;
LETTER;
METASTASIS;
METASTASIS POTENTIAL;
OUTCOME ASSESSMENT;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
PROSTATE CANCER;
TREATMENT OUTCOME;
MALE;
PROSTATIC NEOPLASMS;
ANDROGEN ANTAGONISTS;
ANTINEOPLASTIC AGENTS;
HUMANS;
MALE;
PROSTATIC NEOPLASMS;
TAXOIDS;
|
|
EID: 84996572296
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1511800 Document Type: Letter |
|
Times cited : (3)
|
|
References (3)
|
